Odonate Therapeutics, which is developing an oral chemotherapy drug for breast cancer, raised $150 million by offering 6.3 million shares at $24, the low end of the range of $24 to $27. Odonate Therapeutics plans to list on the Nasdaq under the symbol ODT. Goldman Sachs, Jefferies and Cowen & Company acted as lead managers on the deal.
